Prospective observational study
Data collected forward in time can identify associations and generate signals.
Research library
Emerging research in special populations
Explore emerging clinical data in transplant and refractory anaemia. These studies are not part of the approved indication.
For healthcare professionals · Emerging research, not an expansion of the approved indication.
Rx
Approved indication: anaemia in adult patients with chronic kidney disease on dialysis and not on dialysis.
Understanding the evidence levels
Retrospective case series
Past records can generate hypotheses but are vulnerable to bias.
Single-centre case series
Small numbers from one centre offer signals with very limited generalisability.
Emerging research in focus
1Prospective observational study
Post-kidney-transplant anaemia
n=58Desidustat n=30EPO n=288 weeks
Real-world experience with desidustat in kidney transplant recipients with Hb below 10 g/dL.
Desidustatn = 30
vsEPOn = 28
Treatment based on nephrologist discretion
Key limitations
- Hb improvement in both groups
- No adverse events reported in short follow-up
- Observational allocation and off-label transplant use
Bhavsar H et al. Desidustat in post-kidney transplant anaemia: A real-world observational study. Saudi J Kidney Dis Transpl. 2025;36(3):637–644.
2Retrospective case series
EPO-associated pure red cell aplasia
14 enrolled12 followed9 respondedMedian 4 months
Fourteen CKD patients were reported; twelve were available for follow-up and nine responded.
Outcomes
Denominator note14Enrolled12Available for follow-up9Responded
Median time to response: 4 months
9 responders among 14 enrolled = 64%.
9 responders among 12 followed = 75%.
Important limitations
- Retrospective design
- Limited anti-EPO antibody testing
- Repurposing hypothesis requiring randomised trials
Gupte R et al. Desidustat in erythropoietin-associated pure red cell aplasia in patients with chronic kidney disease. Kidney Int Rep. 2025;10(1):51–57.
3Single-centre case series
Parvovirus B19 after kidney transplant
n=10Adjunct treatmentUncontrolled
Ten recipients received desidustat as adjunct therapy within a multimodal treatment approach.
Treatment approach (multimodal)
The authors call for further studies.Desidustat(adjunct)+
Changes inimmunosuppression+
IVIgIVIg(as needed)+
Transfusionsupport
Interpretive context
- Immunosuppression changes
- IVIg where needed
- Transfusion support
- Independent contribution cannot be determined
Bajpai J et al. Adjunct desidustat for parvovirus B19-associated refractory anaemia in kidney transplant recipients. Indian J Nephrol. 2025;35(2):112–118.
Research questions still open
Search the research library
Filter and explore all emerging research.
| Study | Population | Design | Year | Topic | Interpretive status |
|---|---|---|---|---|---|
| Desidustat in post-kidney-transplant anaemia | Kidney transplant recipients | Prospective observational | 2025 | Anaemia after transplant | Signal-generating; off-label context |